BioXcel Therapeutics/BTAI

$3.06

-0.33%
-
1D1W1MYTD1YMAX

About BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BXCL501 is also being developed for the acute treatment of agitation associated with Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. Under its subsidiary, OnkosXcel Therapeutics, LLC, the Company is developing BXCL701, an investigational, oral innate immune activator that is being developed as a potential therapy for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Ticker

BTAI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Vimal Mehta

Employees

183

Headquarters

New haven, United States

BTAI Metrics

BasicAdvanced
$93.27M
Market cap
-
P/E ratio
-$7.36
EPS
0.41
Beta
-
Dividend rate

What the Analysts think about BTAI

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 8 analysts.
353.59% upside
High $25.00
Low $4.00
$3.06
Current price
$13.88
Average price target

BTAI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-16,800% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$300K
-25%
Net income
$-50.4M
-5.79%
Profit margin
-16,800%
25.61%

BTAI Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 31.9%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$1.95
-$1.84
-$1.83
-$1.72
-
Expected
-$1.45
-$1.62
-$1.75
-$1.30
-$0.92
Surprise
34.82%
13.71%
4.52%
31.9%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell BioXcel Therapeutics stock

Buy or sell BioXcel Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing